1. Search Result
Search Result
Results for "

RXR

" in MedChemExpress (MCE) Product Catalog:

53

Inhibitors & Agonists

1

Peptides

8

Natural
Products

3

Recombinant Proteins

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-144377

    RAR/RXR Neurological Disease Metabolic Disease Cancer
    RXR antagonist 1 (compound 6a) is a retinoid X receptor (RXR) modulator. RXR antagonist 1 shows potent RXR-antagonistic activity, with a pA2 of 8.06. RXR antagonist 1 can be used for type 2 diabetes research .
    RXR antagonist 1
  • HY-107399
    CD3254
    3 Publications Verification

    RAR/RXR Metabolic Disease Cancer
    CD3254 a potent and selective retinoid-X-receptor (RXR) agonist .
    CD3254
  • HY-14171
    Bexarotene
    Maximum Cited Publications
    19 Publications Verification

    LGD1069

    RAR/RXR Autophagy Cancer
    Bexarotene (LGD1069) is a high-affinity and selective retinoid X receptors (RXR) agonist with EC50s of 33, 24, 25 nM for RXRα, RXRβ, and RXRγ, respectively. Bexarotene shows limited affinity for RAR receptors (EC50 >10000 nM) . Bexarotene can be used for the research of cutaneous T-cell lymphoma.
    Bexarotene
  • HY-162162

    RAR/RXR Neurological Disease Metabolic Disease Cancer
    RXR agonist 1 (Compound 33) is a highly selective RXR agonist, with EC50s of 9 nM, 18 nM, and 11 nM for RXRα, RXRβ, and RXRγ, respectively. RXR agonist 1 binds to RXR with high affinity (Kd = 0.03 μM) .
    RXR agonist 1
  • HY-144383

    RAR/RXR Others
    RXR antagonist 2 (compound 6b) is a potent antagonist of RXR with a Ki and Kd of 0.391 and 0.281 μM. RXR antagonist 2 has the potential for the research of RXR related diseases .
    RXR antagonist 2
  • HY-153165

    Others Others
    RXR antagonist 5 (compound 22) is a selective retinoic acid X receptor (RXR) antagonist with binding potential to RXR evaluated by modeling.
    RXR antagonist 5
  • HY-162827

    RAR/RXR Apoptosis Cancer
    RAR/RXR agonist-1 (compound 7) is a chlorinated retinoic acid isomer, a selective RARα agonist and a partial RXRα agonist. RAR/RXR agonist-1 can activate RXRα and induce G2/M arrest and apoptosis in cancer cells .
    RAR/RXR agonist-1
  • HY-155437

    RAR/RXR Others
    NEt-iFQ is a fluorescent retinoid X receptor (RXR) agonist with potent solvatochromic properties. NEt-iFQ selectively binds to RXR-LBP and fluoresces .
    NEt-iFQ
  • HY-14171R

    RAR/RXR Autophagy Cancer
    Bexarotene (Standard) is the analytical standard of Bexarotene. This product is intended for research and analytical applications. Bexarotene (LGD1069) is a high-affinity and selective retinoid X receptors (RXR) agonist with EC50s of 33, 24, 25 nM for RXRα, RXRβ, and RXRγ, respectively. Bexarotene shows limited affinity for RAR receptors (EC50 >10000 nM) . Bexarotene can be used for the research of cutaneous T-cell lymphoma.
    Bexarotene (Standard)
  • HY-W107616

    Endogenous Metabolite Others
    3,7,11,15-Tetramethyl-2-hexadecen-1-ol can be used to synthesize vitamin E and vitamin E's precursor vitamin K1. 3,7,11,15-Tetramethyl-2-hexadecen-1-ol regulates transcription in cells through the transcription factor PPAR-alpha and the retinoid X receptor (RXR)43 .
    3,7,11,15-Tetramethyl-2-hexadecen-1-ol
  • HY-108522
    PA452
    1 Publications Verification

    RAR/RXR Metabolic Disease
    PA452, retinoic X receptor (RXR) specific antagonist, inhibits the effect of Retinoic acid (RA) on Th1/Th2 development .
    PA452
  • HY-108523

    UVI 2112

    RAR/RXR Metabolic Disease
    LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR .
    LG100754
  • HY-15340
    LG100268
    2 Publications Verification

    LG268

    RAR/RXR Autophagy Metabolic Disease
    LG100268 (LG268) is a potent, selective and orally active retinoid X receptor (RXR) agonist with EC50 values of 4 nM, 3 nM, and 4 nM for RXR-α, RXR-β, and RXR-γ, respectively . LG100268 displays >1000-fold selectivity for RXR over RAR, the Ki values are 3.4 nM, 6.2 nM and 9.2 nM for RXR-α, RXR-β, and RXR-γ, respectively . LG100268 activates RXR homodimers to induce transcriptional activation. LG100268 can be used for the study of lung carcinogenesisy .
    LG100268
  • HY-104070

    RAR/RXR Autophagy Cancer
    LG-100064 is a retinoid-X-receptor (RXR) agonist, with EC50s of 330 nM, 200 nM, and 260 nM for RXRα, RXRβ and RXRγ; LG-100064 can be used in the research of cancer.
    LG-100064
  • HY-117182

    Apoptosis VD/VDR RAR/RXR Metabolic Disease Inflammation/Immunology Cancer
    LG190178 is a non-steroidal vitamin D receptor (VDR) ligand that can induce the formation of heterodimer complexes between VDR and retinoid X receptor (RXR), stabilizing the agonistic conformation of the VDR ligand-binding domain and promoting its interaction with co-activators. LG190178 has functions in regulating calcium homeostasis, bone mineralization, as well as cell proliferation, differentiation, and apoptosis, making it useful for research in psoriasis, osteoporosis, and cancer .
    LG190178
  • HY-107413

    BMS-649

    RAR/RXR Cancer
    SR11237 (BMS-649) is a potent retinoid X receptor (RXR)-selective agonist that is devoid of any RAR activity. SR11237 can cause RXR/RXR homodimers to form and transactivate a reporter gene containing a RXR-response element .
    SR11237
  • HY-108525

    RAR/RXR Cancer
    Fluorobexarotene (compound 20) is a potent retinoid-X-receptor (RXR) agonist, with a Ki value of 12 nM and an EC50 value of 43 nM for RXRα receptor. Fluorobexarotene possesses an apparent RXR binding affinity that is 75% greater than Bexarotene .
    Fluorobexarotene
  • HY-149085

    RAR/RXR Cancer
    XS-060 is a potent anticancer agent and RXRα antagonist. XS-060 significantly induces RXRα-dependent mitotic arrest by inhibiting pRXRα-PLK1 interaction. XS-060 inhibits p-RXRα interaction with PLK1 but has no effect on RXRα heterodimerization with RARγ. XS-060 inhibits the in situ interaction between p-RXRα and PLK1 at the centrosome .
    XS-060
  • HY-13717

    IRX4204; NRX194204; VTP 194204

    RAR/RXR Apoptosis Inflammation/Immunology Cancer
    AGN194204 (IRX4204) is an orally active and selective RXR agonist with Kd values 0.4 nM, 3.6 nM and 3.8 nM and EC50s of 0.2 nM, 0.8 nM and 0.08 nM for RXRα, RXRβ and RXRγ, respectively. AGN194204 is inactive against RAR. AGN194204 has anti-inflammatory and anticarcinogenic actions .
    AGN194204
  • HY-108524

    RAR/RXR Metabolic Disease Inflammation/Immunology Cancer
    LG101506 is a selective and orally active RXR modulator with a Ki of 2.7 nM for RXRα. LG101506 can be used for the research of type 2 diabetes and cancer .
    LG101506
  • HY-107500
    UVI 3003
    5 Publications Verification

    RAR/RXR Autophagy Others
    UVI 3003 is a highly selective antagonist of retinoid X receptor (RXR), and inhibits xenopus and human RXRα in Cos7 cells, with IC50s of 0.22 and 0.24 μM, respectively.
    UVI 3003
  • HY-107436
    LE135
    1 Publications Verification

    RAR/RXR TRP Channel Neurological Disease Cancer
    LE135 is a potent RAR antagonist that binds selectively to RARα (Ki of 1.4 μM) and RARβ (Ki of 220 nM), and has a higher affinity to RARβ. LE135 is highly selective over RARγ, RXRα, RXRβ and RXRγ. LE135 is also a potent TRPV1 and TRPA1 receptors activator with EC50s of 2.5?μM and 20?μM, respectively .
    LE135
  • HY-N13361

    RAR/RXR Neurological Disease
    Elodeoidileon A is an agonist for RXRα, that interacts with RXRα-LBD protein with a dissociation constant Kd of 5.85 μM. Elodeoidileon A promotes the expression of ATP-binding cassette transporter A1 (ABCA1). Elodeoidileon A reveals the potential in Alzheimer's disease research .
    Elodeoidileon A
  • HY-153980

    RAR/RXR COX Inflammation/Immunology
    K-80001 is an RXRα-binder and COX-1/2 inhibitor, with IC50s of with an IC50 of 82.9μM, 3.4μM, 1.2μM for RXRα, COX-1 and COX-2, respectively .
    K-80001
  • HY-N2992

    RAR/RXR Cancer
    16α-Hydroxytrametenolic acid, a natural triterpene, is a potential retinoid X receptor (RXR) selective agonist .
    16α-Hydroxytrametenolic acid
  • HY-117926

    RAR/RXR Cancer
    AGN 191701 is a selective retinoic acid X receptor (RXR) agonist that causes liver enlargement in rats without hepatocellular necrosis .
    AGN 191701
  • HY-149086

    RAR/RXR Apoptosis PARP Bcl-2 Family Cancer
    BPA-B9 is a RXRα ligand and antagonist targeting the pRXRα-PLK1 interaction. BPA-B9 has excellent RXRα-binding affinity (KD=39.29 ± 1.12 nM). BPA-B9 inhibits the proliferation of cancer cells by inducing mitotic arrest and cell apoptosis .
    BPA-B9
  • HY-101953

    D'Orenone

    RAR/RXR Others
    β-Apo-13-carotenone (D'Orenone) is a naturally occurring β-apocarotenoid functioned as an antagonist of RXRα.
    β-Apo-13-carotenone
  • HY-16685

    RAR/RXR Autophagy Cancer
    AGN 205327 is a potent synthetic RARs agonist with EC50 of 3766/734/32 nM for RARα/β/γ respectively; no inhibition on RXR.
    AGN 205327
  • HY-133739

    RAR/RXR Cancer
    NBD-125 (B-12), a berberine analogue, is an RXRα activator, with an IC50 of 31.10 μM in KM12C cell .
    NBD-125
  • HY-111573

    RAR/RXR Others
    Anticancer agent 168 is an orally active retinoic acid receptor (RAR/RXR) beta2 agonist with ameliorating effects on spinal cord injury (SCI) .
    KCL-286
  • HY-108520

    RAR/RXR Apoptosis Cancer
    HX630 is a potent retinoic acid X receptor (RXR) agonist, can induce apoptosis, has anti-tumor effect, and can be used in Cushing's disease research .
    HX630
  • HY-120875

    RAR/RXR Neurological Disease
    HX600 is a synthetic agonist for RXR (Retinoid X Receptor) heterodimer complex. HX600 prevents ischemia-induced neuronal damage. HX600 has orally bioactivity .
    HX600
  • HY-118364

    RAR/RXR Metabolic Disease
    AGN 190727 is a structural isomer of AGN 190121 and has no activating effect on RAR/RXR. AGN 190121 is a RAR-specific agonist that causes a dose-dependent increase in serum triglycerides, leading to hypertriglyceridemia.
    AGN 190727
  • HY-N0163
    Magnolol
    4 Publications Verification

    RAR/RXR PPAR Autophagy Bacterial Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Magnolol, a natural lignan isolated from the stem bark of Magnolia officinalis, is a dual agonist of both RXRα and PPARγ, with EC50 values of 10.4 µM and 17.7 µM, respectively.
    Magnolol
  • HY-14171S

    LGD1069 d4

    RAR/RXR Autophagy Cancer
    Bexarotene-d4 is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma[1][2][3][4][5].
    Bexarotene-d4
  • HY-153832

    RAR/RXR NO Synthase Cancer
    MSU-42011 is an orally active retinoid X receptor (RXR) agonist. MSU-42011 inhibits the iNOS activity and reduces the expression of p-ERK protein. MSU-42011 has immunomodulatory and antitumor activity .
    MSU-42011
  • HY-163801

    Nuclear Hormone Receptor 4A/NR4A Neurological Disease
    Nurr1 agonist 9 (Compound 36) is an agonist for Nurr1 with an EC50 of 0.090 µM and a Kd of 0.17 µM. Nurr1 agonist 9 activates the Nurr1 homodimer (NurRE, EC50=0.094 µM) and the Nurr1-RXR heterodimer (DR5, EC50=0.165 µM). Nurr1 agonist 9 induces the expression of Nurr1-regulated tyrosine hydroxylase (TH) in organoid Parkinson's Disease model. Nurr1 agonist 9 is human brain endothelial cell barrier prmeable .
    Nurr1 agonist 9
  • HY-10291
    Tarenflurbil
    3 Publications Verification

    (R)-Flurbiprofen; MPC7869

    RAR/RXR Autophagy Neurological Disease Inflammation/Immunology Cancer
    Tarenflurbil ((R)-Flurbiprofen) is the R-enantiomer of the racemate NSAID Flurbiprofen, Tarenflurbil ((R)-Flurbiprofen) inhibits the binding of [ 3H]9-cis-RA to RXRα LBD with IC50 of 75 μM. Tarenflurbil can be used for Alzheimer's disease research.
    Tarenflurbil
  • HY-15128
    9-cis-Retinoic acid
    1 Publications Verification

    Alitretinoin

    RAR/RXR Apoptosis Endogenous Metabolite Neurological Disease Inflammation/Immunology Cancer
    9-cis-Retinoic acid (ALRT1057), a vitamin A derivative, is a potent RAR/RXR agonist. 9-cis-Retinoic acid induces apoptosis, regulates cell cycle and has anticancer, anti-inflammatory and neuroprotection activities .
    9-cis-Retinoic acid
  • HY-108530

    RAR/RXR Cancer
    MM11253 is a potent and selective RARγ antagonist with an IC50 of 44 nM. MM11253 has lower inhibition of RARα, RARβ and RXRα. MM11253 blocks the growth inhibitory effects of RARγ-selective agonists .
    MM11253
  • HY-N0163R

    RAR/RXR PPAR Autophagy Bacterial Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Magnolol (Standard) is the analytical standard of Magnolol. This product is intended for research and analytical applications. Magnolol, a natural lignan isolated from the stem bark of Magnolia officinalis, is a dual agonist of both RXRα and PPARγ, with EC50 values of 10.4 μM and 17.7 μM, respectively.
    Magnolol (Standard)
  • HY-117376

    UAB30

    RAR/RXR Cancer
    (all-E)-UAB30 (UAB30) is an retinoid X receptor (RXR) selective agonist.(all-E)-UAB30 shows anti-proliferation activity for MyLa, HuT 78, and HH cells with the IC50 of 34.7, 5.1, and 22.4 μM respectively .
    (all-E)-UAB30
  • HY-121671

    Others Neurological Disease
    TBTC is a selective agonist with the activity of improving behavioral deficits in Alzheimer's disease model mice. TBTC can effectively activate the heterodimerization of RXRα with LXRα or PPARγ. TBTC stimulates the expression of apoE, ABCA1, and ABCG1 genes and reduces Aβ content in cells and animal models .
    TBTC
  • HY-115408

    9(R)-Hydroxyeicosatetraenoic acid

    Others Others
    9(R)-HETE is an enantiomer which makes up 50% of (±)9-HETE. At a concentration of 300 nM, 9(R)-HETE activates RXRγ-dependent transcription 1.5 fold relative to a control.1 Stereochemical assignment of the (R) enantiomer is based on comparison of chiral HPLC retention times to published results.
    9(R)-HETE
  • HY-10291R

    RAR/RXR Autophagy Neurological Disease Inflammation/Immunology Cancer
    Tarenflurbil (Standard) is the analytical standard of Tarenflurbil. This product is intended for research and analytical applications. Tarenflurbil ((R)-Flurbiprofen) is the R-enantiomer of the racemate NSAID Flurbiprofen, Tarenflurbil ((R)-Flurbiprofen) inhibits the binding of [3H]9-cis-RA to RXRα LBD with IC50 of 75 μM. Tarenflurbil can be used for Alzheimer's disease research.
    Tarenflurbil (Standard)
  • HY-116248

    RAR/RXR Apoptosis Cancer
    Ro 41-5253 is an orally active selective retinoic acid receptor alpha (RARα) antagonist. Ro 41-5253 can bind RARα without inducing transcription or affecting RAR/RXR heterodimerization and DNA binding. Ro 41-5253 can inhibit cancer cell proliferation and induce apoptosis, has antitumor activity .
    Ro 41-5253
  • HY-B2167R

    Endogenous Metabolite Neurological Disease Cancer
    Docosahexaenoic acid (Standard) is the analytical standard of Docosahexaenoic acid. This product is intended for research and analytical applications. Docosahexaenoic Acid (DHA) is an omega-3 fatty acid abundantly present brain and retina. It can be obtained directly from fish oil and maternal milk. In Vitro: Docosahexaenoic acid (DHA) is essential for the growth and functional development of the brain in infants. DHA is also required for maintenance of normal brain function in adults. The inclusion of plentiful DHA in the diet improves learning ability and memory . DHA is an essential requirement in every step of brain development like neural cell proliferation, migration, differentiation, synaptogenesis. The multiple double bonds and unique structure allow DHA to impart special membrane characteristics for effective cell signaling. Many development disorders like dyslexia, autism spectrum disorder, attention deficit hyperactivity disorder, schizophrenia etc. are causally related to decreased level of DHA . DHA is a potent RXR ligand inducing robust RXR activation already at low micro molar concentrations. The EC50 for RXRα activation by DHA is about 5-10 μM fatty acid . In Vivo: Docosahexaenoic acid administration over 10 weeks significantly reduces the number of reference memory errors, without affecting the number of working memory errors, and significantly increases the docosahexaenoic acid content and the docosahexaenoic acid/arachidonic acid ratio in both the hippocampus and the cerebral cortex . DHA treatment exerts neuroprotective actions on an experimental mouse model of PD. There is a decrease tendency in brain lipid oxidation of MPTP mice but it does not significantly .
    Docosahexaenoic acid (Standard)
  • HY-132334S

    RAR/RXR Apoptosis Neurological Disease Inflammation/Immunology Cancer
    9-cis-Retinoic acid-d5 is the deuterium labeled 9-cis-Retinoic acid. 9-cis-Retinoic acid (ALRT1057), a vitamin A derivative, is a potent RAR/RXR agonist. 9-cis-Retinoic acid induces apoptosis, regulates cell cycle and has anticancer, anti-inflammatory and neuroprotection activities[1][2][3][4][5][6].
    9-cis-Retinoic acid-d5
  • HY-N10361

    RAR/RXR PPAR Cancer
    Drupanin is an orally active selective AKR1C3 enzyme inhibitor and an RXRα agonist with an EC50 value of 4.8 μM, which is isolated from green propolis. Drupanin also activates PPARγ moderately. Drupanin induces adipogenesis and elevates aP2 mRNA levels in 3T3-L1 fibroblasts Drupanin has the potential for the research of breast and prostate cancers .
    Drupanin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: